A review of recent improvement in allogeneic hematopoietic cell transplantation for acute myeloid leukemia

At present, allogeneic stem cell transplantation (allo-HSCT) is a very effective and unique method for the treatment of some malignant and non-malignant blood disorders. However, therapeutic approaches with the potential to reduce disease relapse include advances in induction chemotherapy, new preparative regimens, as well as the evolving concept of post-transplant maintenance. Despite these advances, disease recurrence remains a major cause of graft failure. Current evidence suggests that allo-HSCT is increasingly offered to older patients, including those above ۷۰ years of age with acute myeloid leukemia (AML). On the other hand, the intensification of standard drug dosage and safer allogeneic methods of HSCT allow a larger proportion of patients to achieve a sustainable recovery. Therefore, there is a need to better understand the underlying mechanisms as well as to develop new strategies for prevention and treatment in order to improve allo-HSCT outcomes. In this study, we reviewed recent advances in allo-HSCT in patients with AML.

کلیدواژه ها:

Acute myeloid leukemia ، allogeneic hematopoietic cell transplantation (allo-HSCT)